A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Receiving Oral Venetoclax Tablets in Combination With Subcutaneously (SC) or Intravenously (IV) Injected Azacitidine in Colombia
- Conditions
- Acute Myeloid Leukemia
- First Posted Date
- 2022-10-19
- Last Posted Date
- 2025-08-08
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 70
- Registration Number
- NCT05587049
- Locations
- 🇨🇴
Fundación Santa Fé De Bogotá /ID# 248563, Bogotá, Cundinamarca, Colombia
🇨🇴Fundación Valle Del Lili /ID# 248294, Cali, Valle Del Cauca, Colombia
🇨🇴Hospital Pablo Tobón Uribe /ID# 248569, Medellín, Antioquia, Colombia
Cytokine-Induced Memory-Like Natural Killer Cells (CIML-NK) for Relapsed & Refractory Acute Myeloid Leukemia (AML)
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Drug: CIML-NK Cells
- First Posted Date
- 2022-10-14
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- Children's Hospital Medical Center, Cincinnati
- Target Recruit Count
- 20
- Registration Number
- NCT05580601
- Locations
- 🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
An Open, Single Center, Randomized Controlled Clinical Study of UCB (Cord Blood) in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML)
- Conditions
- UCB (Cord Blood) Microtransplantation in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML)
- First Posted Date
- 2022-10-13
- Last Posted Date
- 2022-10-13
- Lead Sponsor
- Zhongnan Hospital
- Target Recruit Count
- 57
- Registration Number
- NCT05577611
- Locations
- 🇨🇳
Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China
A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia
- Conditions
- Acute Myeloid Leukemia (AML)FLT3-mutated Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2022-08-30
- Last Posted Date
- 2025-08-12
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 70
- Registration Number
- NCT05520567
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸City of Hope Nat'l Medical Center, Duarte, California, United States
🇺🇸Univ. of California - Irvine, Irvine, California, United States
STI-6129 CD38 ADC for the Treatment of Patients With Relapsed or Refractory Systemic ALL Amyloidosis
- Conditions
- Refractory T Acute Lymphoblastic LeukemiaAcute Myeloid Leukemia (AML)
- Interventions
- Drug: Part 1 (STI-6129)Drug: Part 2 (STI-6129)
- First Posted Date
- 2022-08-29
- Last Posted Date
- 2023-08-31
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT05519527
Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies
- Conditions
- Multiple Myeloma (MM)B-cell Acute Lymphoblastic Leukemia (B-ALL)Acute Myeloid Leukemia (AML)B-cell Non-Hodgkin's Lymphoma (B-NHL)T-Cell Leukemia/Lymphoma, Adult
- Interventions
- First Posted Date
- 2022-08-24
- Last Posted Date
- 2023-03-01
- Lead Sponsor
- Shanghai Pudong Hospital
- Registration Number
- NCT05513612
- Locations
- 🇨🇳
Shanghai Pudong Hospital, Fudan University Affiliated Pudong Medical Center, Shanghai, Shanghai, China
Administration of Anti-siglec-6 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML)
- Conditions
- Acute Myeloid Leukemia RefractoryAcute Myeloid Leukemia, in Relapse
- Interventions
- Drug: anti-siglec-6 CAR-T cell therapy
- First Posted Date
- 2022-08-04
- Last Posted Date
- 2022-08-04
- Lead Sponsor
- Xuzhou Medical University
- Target Recruit Count
- 20
- Registration Number
- NCT05488132
- Locations
- 🇨🇳
Kailin Xu, Xuzhou, Jiangsu, China
Healthcare Resource Utilization in Adults Diagnosed With Acute Myeloid Leukemia (AML)
- First Posted Date
- 2022-08-04
- Last Posted Date
- 2022-11-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 81
- Registration Number
- NCT05488613
- Locations
- 🇫🇮
Novartis Investigative Site, Helsinki, Finland
Studying Conditioning Regimen In Pediatric Transplantation - AML , SCRIPT-AML
- Conditions
- Stem Cell TransplantationAcute Myeloid Leukemia (AML) in Remission
- Interventions
- First Posted Date
- 2022-07-28
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Vastra Gotaland Region
- Target Recruit Count
- 170
- Registration Number
- NCT05477589
- Locations
- 🇧🇪
L'Hôpital Universitaire des Enfants Reine Fabiola (HUDERF), Brussels, Belgium
🇧🇪Cliniques Universitaires Saint-Luc (CUSL), Brussels, Belgium
🇧🇪Department of Pediatric Hematology, Oncology and SCT, Ghent University Hospital, Ghent, Belgium
A Phase 1 Study of WU-NK-101 in Patients With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)
- First Posted Date
- 2022-07-22
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Wugen, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT05470140
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸Stanford Healthcare, Palo Alto, California, United States
🇺🇸Norton Health Care, Louisville, Kentucky, United States